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Comparative gut microbiota and resistome
profiling of intensive care patients
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decontamination and healthy subjects
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Evelien A. N. Oostdijk1, Rob J. L. Willems1, Marc J. M. Bonten1, Mark W. J. van Passel3,7, Hauke Smidt3
and Willem van Schaik1,8*
Abstract
Background: The gut microbiota is a reservoir of opportunistic pathogens that can cause life-threatening infections
in critically ill patients during their stay in an intensive care unit (ICU). To suppress gut colonization with
opportunistic pathogens, a prophylactic antibiotic regimen, termed “selective decontamination of the digestive
tract” (SDD), is used in some countries where it improves clinical outcome in ICU patients. Yet, the impact of ICU
hospitalization and SDD on the gut microbiota remains largely unknown. Here, we characterize the composition of
the gut microbiota and its antimicrobial resistance genes (“the resistome”) of ICU patients during SDD and of
healthy subjects.
Results: From ten patients that were acutely admitted to the ICU, 30 fecal samples were collected during ICU stay.
Additionally, feces were collected from five of these patients after transfer to a medium-care ward and cessation of
SDD. Feces from ten healthy subjects were collected twice, with a 1-year interval. Gut microbiota and resistome
composition were determined using 16S rRNA gene phylogenetic profiling and nanolitre-scale quantitative PCRs.
The microbiota of the ICU patients differed from the microbiota of healthy subjects and was characterized by lower
microbial diversity, decreased levels of Escherichia coli and of anaerobic Gram-positive, butyrate-producing bacteria
of the Clostridium clusters IV and XIVa, and an increased abundance of Bacteroidetes and enterococci. Four
resistance genes (aac(6′)-Ii, ermC, qacA, tetQ), providing resistance to aminoglycosides, macrolides, disinfectants, and
tetracyclines, respectively, were significantly more abundant among ICU patients than in healthy subjects, while a
chloramphenicol resistance gene (catA) and a tetracycline resistance gene (tetW) were more abundant in healthy
subjects.
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* Correspondence: w.vanschaik@bham.ac.uk
†Equal contributors
1Department of Medical Microbiology, University Medical Center Utrecht,
Utrecht, The Netherlands
8Institute of Microbiology and Infection, University of Birmingham,
Edgbaston, Birmingham B15 2TT, United Kingdom
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Buelow et al. Microbiome  (2017) 5:88 
DOI 10.1186/s40168-017-0309-z
(Continued from previous page)
Conclusions: The gut microbiota of SDD-treated ICU patients deviated strongly from the gut microbiota of healthy
subjects. The negative effects on the resistome were limited to selection for four resistance genes. While it was not
possible to disentangle the effects of SDD from confounding variables in the patient cohort, our data suggest that
the risks associated with ICU hospitalization and SDD on selection for antibiotic resistance are limited. However, we
found evidence indicating that recolonization of the gut by antibiotic-resistant bacteria may occur upon ICU
discharge and cessation of SDD.
Keywords: Anti-bacterial agents, Antibiotic prophylaxis, Drug resistance, Microbial, Intensive care, Microbiome
Background
The human gut microbiota comprises 1013–1014 bacter-
ial cells that belong to hundreds of different species. The
gut microbiota plays an important role in numerous
metabolic, physiological, nutritional, and immunological
processes of the human host [1]. In healthy individuals,
the gut microbiota mostly consists of bacteria that have
a commensal or mutualistic relationship with the human
host. Critically ill patients, however, frequently have an
extremely dysbiotic gut microbiota that is characterized
by intestinal overgrowth with multi-drug resistant op-
portunistic pathogens of the phylum Proteobacteria (e.g.,
Escherichia coli) and the genus Enterococcus, while the
abundance of commensal Bacteroidetes and Firmicutes
is decreased [2–5]. The high levels of aerobic, opportun-
istic pathogens in the gut during critical illness are likely
contributing to the burden of respiratory and blood-
stream infections with these organisms in critically ill
patients [6].
Selective digestive tract decontamination (SDD) aims
to reduce the risk of nosocomial infections in ICU pa-
tients. SDD is used to eradicate opportunistic pathogens
from the patients, while minimally impacting commensal
bacteria [7]. In SDD, a paste containing the antibiotics
colistin and tobramycin, and the antifungal amphotericin
B, is applied to the oropharynx of ICU patients. The pa-
tients also receive a suspension of colistin, tobramycin,
and amphotericin B via a nasogastric tube. These antimi-
crobials are applied from the day of ICU admission until
ICU discharge. In addition, a third-generation cephalo-
sporin (usually either cefotaxime or ceftriaxone) is
administered intravenously during the first four days
of ICU stay. SDD lowers patient mortality during ICU
stay in settings with a low prevalence of antibiotic
resistance and reduces the costs associated with ICU
hospitalization [8, 9]. Selection of bacteria that are resist-
ant to the antimicrobials used in SDD remains a major
concern [10, 11], although this is not supported by the
results of clinical trials in which conventional culture
techniques were used to screen for antibiotic resistance
among nosocomial pathogens [12].
The patient gut not only is a potential source for op-
portunistic pathogens but also forms a large reservoir
for antibiotic resistance genes, termed the gut resistome
[13–17]. The use of antibiotics may favor the selection
for antimicrobial resistance genes (ARGs) among mem-
bers of the gut microbiota, thus increasing the likelihood
of horizontal spread of ARGs between commensals and
opportunistic pathogens co-residing in the gut [16]. Dur-
ing the administration of SDD, the gut resistome of
patients is monitored by the cultivation of resistant
bacteria from rectal swabs or feces, as part of routine
diagnostics. However, methods that rely on microbial
culture capture only a fraction of the gut resistome,
since anaerobic commensals, which are the main
reservoir of ARGs in the gut microbiota, are difficult to
culture [18–20]. Thus, culture-independent methods are
needed to comprehensively assess the impact of
antibiotic prophylaxis on the microbiota and resistome
of ICU patients.
Here, we used the 16S ribosomal RNA (rRNA) gene-
targeted Human Intestinal Tract Chip (HITChip) and
nanolitre-scale quantitative PCR (qPCR) targeting 81
ARGs to determine the dynamics of gut microbiota
composition and resistome in patients receiving SDD
during ICU hospitalization. We contrast these findings
in ICU patients with the composition of the microbiota
and resistome of healthy subjects.
Methods
Study population
All included patients (n = 10) were acutely admitted to
the ICU of the University Medical Center Utrecht from
the community and had not been hospitalized in the
previous six months, with the exception of patient 105
who was hospitalized for five days prior to transfer to
the ICU and start of SDD. None of the patients were
treated with antibiotics in six months prior to ICU
hospitalization. All patients received SDD from the start
of ICU stay until ICU discharge. SDD consists of
1000 mg of cefotaxime intravenously four times daily for
four days; an oropharyngeal paste containing polymyxin
E, tobramycin, and amphotericin B (each in a 2% con-
centration); and administration of a 10 mL suspension
containing 100 mg polymyxin E, 80 mg tobramycin, and
500 mg amphotericin B via a nasogastric tube, four to
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eight times daily throughout ICU stay. All patients re-
ceived additional antibiotics during ICU stay. Fecal sam-
ples of patients were collected by nursing staff upon
defecation and stored at 4 °C for 30 min to 4 h, after
which the samples were transferred to −80 °C. Seven pa-
tients included here (patient numbers 105, 108, 120,
163, 164, 165, and 169) were also included in a previous
study where the dynamics of two aminoglycoside resist-
ance genes in the gut microbiota of ICU patients was
studied [20]. A total of 30 fecal samples were collected
during ICU stay. Five additional fecal samples were
collected after transfer to a medium-care ward and
cessation of SDD. Additional file 1 includes detailed in-
formation on sampling time points and antibiotic usage
of the ICU patients in this study.
Routine surveillance for colonization with aerobic
Gram-negative bacteria in ICU patients was performed
through culturing of rectal swabs on sheep blood agar and
MacConkey agar. All suspected Gram-negative colonies
were analyzed by Maldi-TOF for species identification.
Antibiotic resistance phenotypes were determined using
the Phoenix system (BD, Franklin Lakes, NJ, USA).
Fecal samples of healthy subjects were collected as
part of the “Cohort study of intestinal microbiome
among Irritable Bowel Syndrome patients and healthy
individuals” (CO-MIC) study at two time points with a
one-year interval between sampling. None of the individ-
uals in this cohort received antibiotics. All included
patients and healthy subjects were adults. Further
demographic information on both cohorts is provided in
Additional file 2. DNA from fecal samples of patients
and healthy subject was isolated as previously described
[21], using two rounds of bead beating and purification
using the QIAamp DNA Stool Mini Kit columns
(Qiagen; Venlo, The Netherlands).
Gut microbiota profiling by HITChip
The HITChip is a validated phylogenetic array produced
by Agilent Technologies (Palo Alto, CA) and developed
at Wageningen University, The Netherlands [22, 23]. It
contains over 4800 oligonucleotides targeting the V1 and
the V6 region of the 16S rRNA gene from 1132 micro-
bial phylotypes present in the human gut [22]. The full-
length 16S rRNA gene was amplified from fecal DNA,
and PCR products were further processed and hybridized
to the microarrays as described previously [24]. Data ana-
lyses were performed using R (www.r-project.org),
including the microbiome package (https://github.com/
microbiome). Bacterial associations in the different patient
groups and healthy subjects were assessed using principal
component analysis (PCA) as implemented in CANOCO
5.0 [25]. Redundancy analysis (RDA) was performed as
implemented in CANOCO 5.0 to determine the associa-
tions between microbiota composition (based on 130
genus-like groups included in the HITChip) and explana-
tory host-associated variables (age, gender, body mass
index (BMI), and sample source, i.e., ICU patient or
healthy subject). Significance of the explanatory variables
was assessed by Monte Carlo permutation testing
(MCPT). Statistical testing for the differences in
microbiota composition between ICU patients and healthy
subjects was performed by the non-parametric Mann-
Whitney U test. All P values were corrected for false dis-
covery rate (FDR) by the Benjamini and Hochberg method
[26], and corrected P values (q) below 0.05 were consid-
ered significant.
Quantification of E. coli by qPCR
qPCRs for the quantification of E. coli were performed
with primers that were previously described [27], using
serial dilutions of genomic DNA of E. coli DH5α to gen-
erate a standard curve. The quantification of 16S rRNA
was performed with primers described in [28]. The PCR
conditions were identical to the qPCR conditions for the
detection of mcr-1 (described below).
qPCR analysis of antibiotic resistance genes
qPCR analysis was performed using the 96.96 BioMark™
Dynamic Array for Real-Time PCR (Fluidigm Corpor-
ation, San Francisco, CA), according to the manufac-
turer’s instructions, with the exception that the
annealing step in the PCR was held at 56 °C. Fecal DNA
was first subjected to 14 cycles of specific target amplifi-
cation using a 0.18-μM mixture of all primer sets, ex-
cluding the 16S rRNA primer sets, in combination with
the Taqman PreAmp Master Mix (Applied Biosystems),
followed by a fivefold dilution prior to loading samples
onto the Biomark array for qPCR. Thermal cycling and
real-time imaging was performed on the BioMark instru-
ment, and Ct values were extracted using the BioMark
Real-Time PCR analysis software.
Target selection, primer design, and primer validation
The primer set used in the qPCR assays covered 81 anti-
microbial resistance genes (ARGs) of 14 resistance gene
classes (Additional file 3). Primers were designed for the
ARGs that are most commonly detected in the gut
microbiota of healthy individuals [14, 15] and clinically
relevant ARGs, including genes encoding extended
spectrum β-lactamases (ESBLs), carbapenemases, and
proteins involved in vancomycin resistance. Primer de-
sign was performed using Primer3 [29] with its standard
settings with a product size of 80–120 bp and a primer
melting temperature of 60 °C. The universal primers for
16S rRNA genes were previously described by Gloor et
al. [28]. Forward and reverse primers were evaluated in
silico for cross hybridization using BLAST [30] and were
cross-referenced against ResFinder [31] to ensure the
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correct identity of the targeted genes. All primers that
aligned with more than ten nucleotides at their 3′ end
to another primer sequence were discarded and rede-
signed. Additionally, all primer sets were aligned to all
resistance genes that were targeted in this PCR analysis
to test for cross hybridization with genes other than the
intended target resistance gene. Primers that aligned
with more than ten nucleotides at their 3′ end sequence
with a non-target resistance gene were discarded and
redesigned. A reference sample consisting of pooled
fecal DNA from different patients was loaded in a series
of fourfold dilutions and was used for the calculation of
primer efficiency. All primers whose efficiency was ex-
perimentally determined to be between 80 and 120%
were used to determine the normalized abundance of
the target genes. The detection limit on the Biomark sys-
tem was set to a CT value of 20, as recommended by the
manufacturer. In addition, to assess primer specificity,
we performed melt curve analysis using the Fluidigm
melting curve analysis software (http://fluidigm-melting-
curve-analysis.software.informer.com/). All PCRs were
performed in triplicate, and sample-primer combinations
were only included in the analysis when all triplicate re-
actions resulted in a CT value below the detection limit.
After completion of the nanolitre-scale qPCR assays,
the transferable colistin resistance gene mcr-1 was de-
scribed [32]. To detect and quantify mcr-1, we developed
primers (qPCR-mcr1-F: 5′-TCGGACTCAAAAGGCGT
GAT-3′ and qPCR-mcr1-R: 5′-GACATCGCGGCATT
CGTTAT-3′) for use in a standard qPCR assay. The
mcr-1 gene was synthesized based on the sequence de-
scribed in [32] by Integrated DNA Technologies
(Leuven, Belgium) and used as a positive control in our
assays. The qPCR was performed using Maxima SYBR
Green/ROX qPCR Master Mix (Thermo Scientific, Leus-
den, The Netherlands) and a StepOnePlus instrument
(Applied Biosystems, Nieuwekerk a/d IJssel, The
Netherlands) with 5 ng DNA in the reaction and the fol-
lowing program: 95 °C for 10 min and subsequently
40 cycles of 95 °C for 15 s and 56 °C for 1 min.
Calculation of normalized and cumulative abundance
Normalized abundance of resistance genes was calcu-
lated relative to the abundance of the 16S rRNA gene
(CTARG − CT16S rRNA), resulting in a log2-transformed
estimate of ARG abundance. Statistical analysis was per-
formed using GraphPad Prism (La Jolla, CA).
Visualization of the qPCR data in the form of a heat
map was performed using Microsoft Excel. Statistical
testing of the differences in the abundance of resistance
genes in ICU patients versus healthy subjects was per-
formed with the non-parametric Mann-Whitney U test
with a false discovery rate (Benjamini Hochberg) <0.05
to correct for multiple testing.
Results
Microbiota dynamics in ICU patients and healthy subjects
Ten ICU patients and ten healthy subjects were included
in this study. There were no statistically significant dif-
ferences between the cohorts in their gender distribution
and BMI. The age of the ICU patients was significantly
(P < 0.05; Mann-Whitney U test) higher (median 57,
interquartile range 49–74) than the age of the healthy
subjects (median 42.5, interquartile range 31–51; Add-
itional file 2). Global changes in the gut microbiota of
healthy subjects and ICU patients were visualized by
principal component analysis (Fig. 1a). The microbiota
profiles of healthy subjects clustered together, indicating
that they had stable and broadly comparable microbiota
profiles, which were clearly distinct from the microbiota
profiles of patients during and after ICU stay. These pro-
files covered a larger area in the PCA plot, indicating
that the differences in the microbiota composition of pa-
tients were larger than that of healthy subjects. The
composition of the gut microbiota in patient samples
collected during and after ICU hospitalization was mark-
edly altered, with samples clustering away from the
healthy controls. RDA showed that both sample source
(i.e., whether samples were taken from ICU patients or
healthy subjects) and, to a lesser extent, BMI signifi-
cantly explained microbiota composition variance (sam-
ple source: q = 0.007; BMI: q = 0.048, Additional file 4).
The other tested variables (age and gender) did not sig-
nificantly contribute to the variability in microbiota
composition. Collectively, the tested variables explained
30% of microbiota composition variance.
The diversity of the microbiota, as quantified by
Shannon’s diversity index, was significantly lower in ICU
patients compared to healthy subjects (5.90 ± 0.20 vs
5.19 ± 0.46, respectively; P < 0.001, Student’s t test). The
diversity of the microbiota of ICU patients was highly
dynamic (Fig. 1b). Several patients (#108, #163, #164,
#165, and #169) experienced a rapid loss of diversity in
the first days of ICU stay. In contrast, the diversity of the
microbiota was more stable in healthy subjects when com-
paring samples that were collected 1 year apart (Fig. 1c).
Compared to healthy subjects, the microbiota of patients
during ICU hospitalization was characterized by a signifi-
cantly higher abundance in the taxa Bacteroidetes and
Bacilli: Enterococcus and a lower abundance of the taxa
Clostridium cluster IV and XIVa (Fig. 1d).
We performed quantitative PCRs to accurately deter-
mine the abundance of E. coli, one of the primary targets
of SDD, in the gut microbiota of patients and healthy
subjects (Fig. 2). The abundance of E. coli in samples of
ICU patients was lower compared to the healthy sub-
jects (p = 0.001; Mann-Whitney U test). Notably, upon
ICU discharge, cessation of SDD, and transfer to a
medium-care ward, the abundance of E. coli rebounded
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in one patient (#105) to levels surpassing those found in
healthy individuals.
During ICU stay, routine surveillance by conventional
microbiological culture was performed on all patients. E.
coli could be cultured from six out of 73 rectal swabs
that were collected during the patients’ ICU stay. Five E.
coli-positive rectal swabs, of patients #43, #105, #108,
#163, and #169, were collected within one day of ICU
admission, while the sixth positive swab (of patient
#165) was collected after 9 days of ICU stay. In addition,
an E. coli strain from patient #105 with an ESBL-
producing and tobramycin-resistant phenotype was
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isolated after ICU discharge, while the patient was in a
medium-care ward. The E. coli strains isolated during
ICU stay were susceptible to cephalosporins and amino-
glycosides. All E. coli strains were susceptible to colistin.
Resistome dynamics in ICU patients and healthy subjects
A total of 46 unique ARGs conferring resistance to 12
different classes of antimicrobials were detected in the
DNA isolated from fecal samples of hospitalized patients
and healthy subjects (Additional file 5). The number of
detected resistance genes per sample ranged between 6
and 38. Eleven resistance genes were detected in >80%
of healthy subjects and critically ill patients. This highly
prevalent set of resistance genes included tetracycline re-
sistance genes (tetO, tetQ, tetM, tetW), two aminoglyco-
side resistance genes (aph(3′)-III and an aadE-like gene),
the bacteroidal β-lactam resistance gene cblA, and the
macrolide resistance gene ermB.
Genes associated with major antibiotic resistance
threats, including those identified by the Centers for
Disease Control, were relatively rare. Genes encoding for
extended-spectrum beta-lactamases (ESBLs) were not
detected in healthy subjects. In two ICU patient samples
(#105C and #108C), however, the ESBL genes blaCTX-M
and blaDHA, respectively, could be detected. Sample
#105C was collected after ICU discharge and cessation
of SDD, while sample #108C was collected after 12 days
of ICU hospitalization and SDD treatment. The carbape-
nemase blaKPC was detected in a single patient (patient
#180), but only in the first sample (collected after
five days in the ICU) and not in the second sample,
which was collected after 16 days of ICU hospitalization.
No other ESBL- or carbapenemase-producing strains
were isolated from the patients during ICU
hospitalization. Other enterobacterial β-lactamases were
found to be widespread in our resistome analysis. The
blaAMPC β-lactamase was present in 37% of samples,
with nine of ten patients and eight of ten healthy sub-
jects having detectable levels of blaAMPC at one or more
sampling points. The blaTEM β-lactamase was present in
26% of samples, corresponding with five of ten patients
and four of ten healthy subjects in which this gene was
detectable at one or more sampling points. None of the
samples were positive for the carbapenemases blaNDM
and blaOXA or the transferable colistin resistance gene
mcr-1. Among resistance genes that are associated with
Gram-positive pathogens, the staphylococcal methicillin
resistance gene mecA was detected in 13 samples from
eight of ten patients, but not in samples of healthy sub-
jects. The vancomycin resistance gene vanB was present
in five samples from three of ten patients and six sam-
ples from four of ten healthy subjects.
A comparison of the abundance of individual ARGs in
samples that were collected during ICU stay, versus
samples from healthy subjects, revealed that four ARGs
(aac(6′)-Ii, ermC, qacA, tetQ) were significantly more
abundant in ICU patients, while two ARGs (catA and
tetW) were significantly more abundant in healthy indi-
viduals (Fig. 3).
Discussion
Current guidelines in The Netherlands recommend top-
ical antibiotic decontamination in ICU patients with an
expected ICU stay of two days or longer. Yet, the original
claim that these interventions do not affect harmless an-
aerobic intestinal bacteria [7] has recently been questioned
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[20, 33]. While culture-based studies did not demonstrate
selection for antibiotic-resistant opportunistic pathogens
during SDD treatment [9, 12, 34, 35], concerns remain
that selection for antibiotic resistance genes occurs in the
gut microbiota of patients that are treated by SDD during
their stay in the ICU.
The current study describes the composition of the
gut microbiota and the resistome of ICU patients receiv-
ing SDD during ICU stay and compares these findings
to the microbiota and resistome of healthy subjects. We
were not able to include an ICU control group that was
not treated with SDD, as this would be a breach of clin-
ical guidelines for ICU patients in our country. For this
reason, it is not possible to disentangle the effects of
SDD from other factors that affect the composition of
the microbiota during ICU stay, including underlying
critical illness, parenteral feeding, and curative antibiotic
therapy.
The gut microbiota of ICU patients in this study was
characterized by a low diversity, the increased abun-
dance of enterococci, and lower abundance of anaerobic
Gram-positive, butyrate-producing bacteria of the Clos-
tridium clusters IV and XIVa. These findings are in line
with previous studies reporting selection for Gram-
positive cocci [12, 20, 36, 37] and depletion of Faecali-
bacterium prausnitzii in ICU patients receiving SDD
[33]. In addition, we were able to demonstrate that the
abundance of E. coli was significantly lower in ICU
patients than in healthy individuals. The suppression of
E. coli in the SDD-treated ICU patients starkly contrasts
with other studies in critically ill patients not receiving
SDD, in which E. coli is present at higher levels than in
healthy individuals [2, 3, 5]. This observation further
supports previous studies which found that SDD is suc-
cessful in suppressing outgrowth of E. coli in the gut
microbiota of ICU patients [8, 9], corresponding to the
original aim of SDD [7].
Notably, levels of E. coli increased again after ICU dis-
charge in two of patients, reaching levels in the gut simi-
lar to, or even surpassing, those in healthy individuals.
These findings suggest that a rapid regrowth or
recolonization of the intestinal tract by E. coli, and pos-
sibly other aerobic Gram-negative bacteria, occurs upon
cessation of prophylactic antibiotic therapy. In one of
the post-ICU samples, an ESBL-producing E. coli strain
was isolated. Indeed, this was the only sample in which
the ESBL blaCTX-M gene was detected in our resistome
analysis. In the only prospective evaluation on the post-
ICU effects of SDD, the implementation of SDD was not
associated with higher infection rates after ICU dis-
charge [38], but further studies are warranted to better
quantify the risks associated with recolonization of the
gut by multi-drug resistant, opportunistic pathogens
upon ICU discharge, and cessation of SDD.
The qPCR-based analysis of the resistome confirms pre-
vious metagenomic studies, in showing that tetracycline
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Fig. 3 Antimicrobial resistance genes present at significantly higher or lower levels in the microbiota of ICU patients, compared to healthy
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and aminoglycoside resistance genes and bacteroidal β-
lactamases are widespread in the human intestinal micro-
biota [14, 15, 18, 20]. Four resistance genes (aac(6′)-Ii,
ermC, qacA, tetQ) were significantly more abundant
among ICU patients than in healthy subjects. The
aac(6′)-Ii gene is a specific chromosomal marker for
the nosocomial pathogen Enterococcus faecium and
provides low-level resistance to aminoglycosides [39]. Its
high abundance in ICU patients is in line with the in-
creased levels of enterococci in the microbiota of the pa-
tients. The increased abundance of the macrolide
resistance gene ermC may have been selected for by the
use of low doses of the macrolide erythromycin, which
was used as an agent to accelerate gastric emptying during
ICU stay in six patients. The increased abundance of tetQ
in the gut microbiota of ICU patients may reflect the
higher abundance of Bacteroidetes in ICU patients versus
healthy subjects, as tetQ is widely distributed on conjuga-
tive transposons in this phylum [40]. Finally, the qacA
gene confers resistance to a number of disinfectants, in-
cluding the biguanidine compound chlorhexidine and the
quaternary ammonium compound benzalkonium chloride
[41, 42]. Disinfectants are widely used in ICUs as cleaning
and infection control agents [43], and their use could se-
lect for qacA in the gut microbiota of patients.
Two resistance genes (catA and tetW) were more
abundant in healthy individuals than in ICU patients.
There is currently little information on the distribu-
tion of the catA gene among bacteria associated with
the human gut microbiota, but the gene was fre-
quently found in human feces in a recent study set in
low-income human habitats [44]. The tetracycline re-
sistance gene tetW is present in Gram-positive anaer-
obic gut commensals [45].
Although SDD improves survival of ICU patients,
its use remains controversial due to the risk for se-
lection of antibiotic resistance among bacteria that
populate the patient gut. In this observational study,
we found little evidence for the selection of high-risk
resistance determinants, like ESBLs, carbapenemases,
or vancomycin resistance genes, in SDD-treated pa-
tients during their stay in the ICU. The increased
abundance of the resistance genes aac(6′)-Ii, ermC,
qacA, and tetQ in SDD-treated ICU patients in our
study could be interpreted as being of limited con-
cern. The first three resistance genes contribute to
resistance in enterococci, either to relatively low con-
centrations of antibiotics (aac(6′)-Ii) or to classes of
antimicrobials that are of limited relevance for the
treatment of enterococcal infections (ermC and
qacA). The tetQ gene provides resistance to tetracy-
clines in Bacteroidetes, but this class of antibiotics is
scarcely used for the treatment of anaerobic infec-
tions [46]. The selection for enterococci occurring in
this patient cohort may be of concern in settings
where vancomycin-resistant enterococci (VRE) are
endemic. VRE is still infrequent in The Netherlands, and
the vanB resistance gene that was detected in both pa-
tients and healthy subjects is most likely associated with
Gram-positive anaerobes [47]. It remains to be deter-
mined whether SDD leads to selection for VRE in coun-
tries where these bacteria are more prevalent.
Conclusions
Our data support the notion that in settings with low
levels of circulating antibiotic resistance genes, ICU
hospitalization and SDD treatment does not lead to the
selection of antibiotic resistance genes with high clinical
relevance. However, it is difficult to generalize these
findings from a Dutch hospital to other countries, where
resistant bacteria are more prevalent. Our study also
illustrates the relative lack of data regarding
recolonization of the gut upon ICU discharge and cessa-
tion of SDD. Future studies into the emergence and
spread of antibiotic resistance genes in ICU patients can
benefit from the qPCR platform used here as it enables
the rapid detection and quantification of antibiotic re-
sistance genes in the gut microbiota. The detection of
high-risk antibiotic resistance genes (encoding, e.g.,
ESBLs, carbapenemases or vancomycin resistance pro-
teins) in the resistome of patients may lead to the imple-
mentation of targeted antibiotic therapy or infection
control measures to minimize the risk for selection and
spread of these resistance genes.
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families (B: bacitracin, C: chloramphenicol; M: macrolides; P, polymyxins; Qa:
quaternary ammonium compounds, S: sulphonamides; Tet: tetracyclines; T:
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